Cannabis Report
Home > Boards > US OTC > Medical - Equipment >

Arrayit Corporation (ARYC)

ARYC RSS Feed
Add ARYC Price Alert      Hide Sticky   Hide Intro
Moderator: techmover, BZstocks, DDStocks, HighYieldStocks, Mykkus, SK510
Search This Board: 
Last Post: 6/19/2018 12:23:11 PM - Followers: 481 - Board type: Free - Posts Today: 110

Welcome to the Ihub Arrayit Corporation (ARYC) board  


Arrayit Corporation (ARYC) is a Silicon Valley biotech company that is currently trading at a low fraction of its actual worth. Please review the listed links, see the actual sales of this Silicon Valley company through their daily updates on Twitter (@Arrayit) and understand the incredible potential that this company has.  

Arrayit Corporation  
927 Thompson Place  
Sunnyvale, CA 94085  
USA  
Phone 408-744-1331  
FAX 408-744-1711  
Email arrayit@arrayit.com  
Web www.arrayit.com

 

Publications and Social Networking:  

Arrayit products have been featured in 5,000+ scientific publications.
Follow Arrayit on Twitter, Facebook, Yahoo Finance, $ARYC and iHub.  

https://twitter.com/arrayit
https://www.facebook.com/Arrayit
https://finance.yahoo.com/quote/ARYC?ltr=1
https://www.youtube.com/ 
Arrayit Corporation News Feed
Arrayit Store
 
 
Corporate Overview
Arrayit Corporation is a leading life sciences company providing innovative products and services to empower scientists and clinicians to explore the human genome as well as the genomes of plants and animals. Arrayit's worldwide business position leverages the company's widely used patented microarray manufacturing platform and revolutionary VIP™ genotyping technology. Nearly every major research center in the world uses Arrayit products including research laboratories, pharmaceutical companies, universities, biotechnology companies, hospitals, government agencies, and nonprofit research organizations. Novel insights into the function of genes and proteins, early stage disease diagnostics, better and safer medicines, and more nutritional crop plants are some of the many aspects of human health empowered by Arrayit technology.
Corporate Philosophy
Arrayit is an exciting and innovative public company that strives to increase shareholder equity by inventing, developing, manufacturing and supplying sophisticated life sciences products and services to an extensive customer base spanning 50 countries. Our corporate philosophy is embodied by a highly skilled, multidisciplinary team of investors, business professionals, scientists, engineers and executive and support staff who place shareholder value, product quality, customer service and price competitiveness as our highest priorities. Arrayit empowers decisive strategic advantage and large return on investment for our customers in the research, pharmaceutical, diagnostic, and health care markets.

Corporate History
Arrayit Corporation was founded in 1993 by Rene' Schena and Todd Martinsky as TeleChem International, Inc, a chemical import and export company specializing in plastics, water soluble fertilizers, alternative fuels, and the life sciences. After several years of successful revenues growth, the company expanded in 1999 by adding Dr. Mark Schena and Paul Haje, who together with Ms. Schena and Mr. Martinsky, founded Arrayit Life Sciences, a division of TeleChem International, Inc. Arrayit sought to build on the opportunities created by the deciphering of the human genome and the rise of microarray technology. Arrayit microarrays are sophisticated glass substrates containing large collections of DNA and protein spots that allow all 25,000 human genes and every major protein in the human body to be analyzed in a few hours. Arrayit VIP™ microarrays enable the analysis of the DNA from 100,000 patients in one day. Since 1999, Arrayit has has build a powerful portfolio of patents, trade secrets, and more than 650 life sciences products. The company was featured on the television series NOVA in 2001, received successive appointments to the Inc. 500 list in 2002 and 2003, and has received numerous local awards including the Rising Star award from the City of Sunnyvale and the Silicon Valley 50 award in 2003. The company changed its name to Arrayit Corporation and began trading on the OTC Bulletin Board in 2009 as ticker symbol ARYC. The company's products and services are used in the life sciences, pharmaceutical, and diagnostics markets, which are estimated at $690 billion in annual revenue.
 


No share increase per CEO (I.E. NO DILUTION)

Authorized: 2,480,000,000 
Outstanding: 1,055,279,527 
Restricted: 11,490,723 
Float: 1,043,788,804 


Standard Registrar and Transfer Company, Inc. 
440 East 400 South, Suite 200 
Salt Lake City, UT 84111 
Phone: 801-571-8844 or 801-596-2150 
Fax: 801-328-4058

Estimated earnings of $8 million last year and it is also located in the heart of Silicon Valley near Apple, Yahoo, AMD, Juniper, MBZ, LinkedIn, Facebook and many, many other leaders of the tech industry. 

2 contracts signed last year for a total of approximately $51 million over the next 3 years ......

No other OTC company has the potential of ARYC  

Arrayit's new corporate headquarters, features 15,000 square feet of modern industrial space including 45 parking spaces, offices, conference rooms, demonstration laboratories, class 100 cleanrooms, and manufacturing and shipping facilities

Arrayit Headquarters Drive By(Click to view)
Arrayit Store sales exceed $55,000,000 all time on 230,706 products and services sold since on-line inception
 

 


 

ARYC also owns 40 million shares of AVDX(Click to visit Advant Diagnostics)

Enabling physicians to make personalized treatment recommendations for cancer patients

Avant Diagnostics, Inc. (formerly known as Theranostics Health, Inc.) is a medical diagnostic technology company focused on commercializing innovative biomarker technologies that have the potential to dramatically improve treatment outcomes in the areas of oncology and neurology. The Company's lead technology, called Theralink(r), was developed to empower cancer treating physicians with actionable information make time sensitive treatment decisions for their patients. Theralink was designed to inform physicans which treatments are likely to be effective for their patients at any given moment in time, and also identify which treamtents are unlikely to be effective. This information has the potential to improve treatment efficacy and reduce side effects by foregoing ineffective therapy.

Cancer tumor biomarker profiling: Driving innovation in personalized medicine

At Avant Diagnostics, our approach is based on more than 10 years of research and development that informs our philosophy the genetic information alone is insufficient to make patient specific treatment recommendations. Our phospho-proteomic approach, which focuses on measuring the quantity and intensity of drug target activation in the tumor tissue following standard biopsy procedures, exploits our understanding of drug-receptor interaction that is the driver of treatment response . Our advanced technology is being developed to reduce the prescription of ineffective, toxic treatments and guide physicians towards therapies that are most likely to lead to positive responses to treatment. Our large panel of markers targeted at already-approved FDA drugs, as well as certain investigational therapies, makes Theralink an invaluable tool for oncologists.

Market opportunity: Cancer biomarkers market expected to reach $33B by 2025

According to Grand View Research, the market for cancer biomarkers is expected to grow from $10.3B in 2016 to $33.7B by 2025, representing a compound annual growth rate (CAGR) of 14.6%. The market is currently comprised primarily of genetic biomarkers that have good predictive value on a population basis, but limited value on an individual patient basis. Proteomic markers represent a growing segment of the cancer biomarker market, and offer the promise to improve individual patient outcomes based upon the individual patient's tumor proteomic profile.

Within the proteomic cancer biomarker category, phosphoprotein analysis represents a uniquely positioned asset class that can more robustly predict treatment outcomes based upon the molecular mechanisms driving tumor growth and treatment resistance. As such, the Company believes it has the potential to be the market leader in this phospho-proteomic subcategory.
 

OvaDx® Ovarian Cancer Diagnostic Test

In Development

Arrayit Diagnostics, Inc. provides the market's first large panel biomarker screening test for ovarian cancer. OvaDx® is a sophisticated microarray-based test that measures the activation of the immune system in blood samples in response to early stage ovarian tumor cell development. Research studies with OvaDx® indicate high sensitivity and specificity for all types and stages of ovarian cancer including stage IA-IV borderline serous, clear cell, endometrioid, mixed epithelial, mucinous, serous, and ovarian adenocarcinoma. Upon FDA approval, Arrayit Diagnostics will offer OvaDx® as an elective test for women seeking greater wellness and for women in the elevated risk category for ovarian cancer. OvaDx® will be used by doctors to advance the forefront of ovarian cancer treatment including improved surgical options, more effective chemotherapies, and to supplement existing tests including CA-125, OVA1®, and transvaginal ultrasound.
 

Human genome

Arrayit Corporation Announces New Clinical Licensure

from the Centers for Medicare and Medicaid Services - 


BIGGEST NEWS IN COMPANY HISTORY

www.nasdaq.com/press-release/arrayit-corporation



Cannabis Report
ARYC
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
ARYC News: Arrayit Corporation Announces Nationwide Allergy Testing Sales and Distribution Network 06/18/2018 05:30:00 AM
ARYC News: Arrayit Corporation Achieves Testing Accuracy Required for Medicare and Medicaid Reimbursement 05/30/2018 08:30:00 AM
ARYC News: Statement of Changes in Beneficial Ownership (4) 05/09/2018 01:55:34 PM
ARYC News: Statement of Ownership (sc 13g) 03/22/2018 02:12:50 PM
ARYC News: Initial Statement of Beneficial Ownership (3) 03/19/2018 06:37:10 PM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
PostSubject
#83953  Sticky Note UPDATED: ARYC Potential revenue streams partial list: BZstocks 06/08/18 09:43:16 AM
#82149  Sticky Note Arrayit Corporation Achieves Testing Accuracy Required for Medicare techmover 05/30/18 08:49:16 AM
#79636  Sticky Note To all who are new to the ARYC DDStocks 05/12/18 01:56:34 PM
#78973  Sticky Note Arrayit Corporation Announces New Clinical Licensure from the HighYieldStocks 05/09/18 08:49:20 AM
#78352  Sticky Note Welcome to all new investors and those inquiring SK510 05/02/18 06:50:16 PM
#78280  Sticky Note Silicon Valley Biotech Mykkus 05/02/18 02:28:23 PM
#85701   Nice to see you Doc. It’s healthy to UndervaluedStocks 06/19/18 12:31:43 PM
#85700   This is Huge $$$$ NEW tweet...Arrayit CLIA clinical team Penny Traders Club 06/19/18 12:31:10 PM
#85699   Nice! will add to the list - BZstocks 06/19/18 12:28:53 PM
#85698   After yesterday some small profit taking and some Doc Hollywood 06/19/18 12:23:11 PM
#85697   ARYC...ADS...They SHOULD know that many of us will ohiotom 06/19/18 12:19:17 PM
#85696   NEW tweet...Arrayit CLIA clinical team confirms July 2 HighYieldStocks 06/19/18 12:17:30 PM
#85695   Is everyone ready? Arrayit CLIA clinical team confirms July UndervaluedStocks 06/19/18 12:10:40 PM
#85694   ARYC....THANK YOU for reminding me why I am ohiotom 06/19/18 12:10:26 PM
#85693   NEW tweet...Arrayit CLIA clinical team confirms July 2 HighYieldStocks 06/19/18 12:08:13 PM
#85692   Thanks bro! mikewazowski 06/19/18 12:04:22 PM
#85690   Last 4 pr's - Huge move in the works: BZstocks 06/19/18 11:54:28 AM
#85689   Got a few minutes? Look here: ScorpGirl 06/19/18 11:50:04 AM
#85688   You are so right...while the MMs' are covering spotlight1 06/19/18 11:49:17 AM
#85687   NEW tweet...Arrayit sales and marketing team reports $10,000 HighYieldStocks 06/19/18 11:47:36 AM
#85686   Arrayit (ARYC) sales and marketing team schedules shareholder UndervaluedStocks 06/19/18 11:46:46 AM
#85685   Repeat maybe, but worth another chew: ScorpGirl 06/19/18 11:40:45 AM
#85684   It is exactly the same people you need mfdesigner 06/19/18 11:40:30 AM
#85683   Everyone should grab 100k each, and lets blow HighYieldStocks 06/19/18 11:39:44 AM
#85682   NEW tweet...Arrayit shipping department ships microarray life sciences HighYieldStocks 06/19/18 11:38:35 AM
#85680   For sure, nicely churning in the .04 range. techmover 06/19/18 11:36:09 AM
#85679   Ready for an update on this tweet: BZstocks 06/19/18 11:32:14 AM
#85678   NEW tweet...Arrayit shipping department ships microarray life sciences HighYieldStocks 06/19/18 11:30:47 AM
#85677   I wouldn’t be shocked TravO 06/19/18 11:28:01 AM
#85676   I think their not done. Very possible.. IMO Jeffpacman 06/19/18 11:26:33 AM
#85675   I’m not counting on anything, just like I Play4keeps2 06/19/18 11:17:31 AM
#85674   Massive for all who are new to ARYC: SK510 06/19/18 11:07:34 AM
#85673   Research Project: Molecular Identification and Characterization of Bacterial MikeCr 06/19/18 11:04:50 AM
#85672   would not count on that...more likely a red The_Free_Nebula 06/19/18 10:57:39 AM
#85671   They are working with the USDA so that MikeCr 06/19/18 10:56:32 AM
#85670   EOD buying spree again today? Play4keeps2 06/19/18 10:50:50 AM
#85669   No bull about it...you know on every board techmover 06/19/18 10:33:48 AM
#85668   Here's a good survey paper in this area mfdesigner 06/19/18 10:33:08 AM
#85667   Sorry, but that’s bull. I’m not negative on CryptoRain 06/19/18 10:32:07 AM
#85666   DOW AND OTHER THINGS HAVE ABSOLUTELY NOTHING TO okwife 06/19/18 10:30:49 AM
#85665   Or, they just don't care to answer. :) techmover 06/19/18 10:29:38 AM
#85664   Arrayit Corporation (OTC: ARYC), a life sciences and UndervaluedStocks 06/19/18 10:29:36 AM
#85663   Not if the test is covered by insurance :) UndervaluedStocks 06/19/18 10:29:01 AM
#85662   I am doing my own DD...but obviously if CryptoRain 06/19/18 10:28:46 AM
#85661   Based on my knowledge and visiting the company Jeffpacman 06/19/18 10:27:48 AM
#85660   I’m trying to grasp the ability to impact CryptoRain 06/19/18 10:26:28 AM
#85659   Arrayit blood cards can be used on every UndervaluedStocks 06/19/18 10:25:16 AM
#85658   If you are TRULY interested in this company, techmover 06/19/18 10:21:55 AM
#85656   Probably would be best if you directed your Doc Hollywood 06/19/18 10:21:06 AM
#85654   I agree. I think the longer it stays Doc Hollywood 06/19/18 10:15:45 AM
#85653   Lets see if 4 holds on the bid The_Free_Nebula 06/19/18 10:15:39 AM
#85652   With the Dow down 370 points and a Sloan89RH 06/19/18 10:15:01 AM
#85651   July 2 FDA approval, then ......$$$$$$$$$$ Arrayit Corporation UndervaluedStocks 06/19/18 10:12:15 AM
#85650   Very nice indeed! I Expect some churning in DDStocks 06/19/18 10:12:14 AM
#85649   this is all retail selling here because they okwife 06/19/18 10:08:49 AM
#85648   With a little review, it appears that Arrayit SK510 06/19/18 10:05:27 AM
PostSubject